Peptide News Digest

HLB RGN-259 SEER-3 Phase 3 Miss, NervGen NVG-291 RESTORE Phase 3 Mid-2026, EndoCyclic ENDO-205 IND Cleared for Endometriosis, Bachem CCO Transition, CROI 2026 GLP-1 + HIV, PharmTech Peptide Manufacturing Feature

HLB RGN-259 SEER-3 miss, NervGen NVG-291 RESTORE Phase 3 mid-2026, EndoCyclic ENDO-205 IND endometriosis, Bachem CCO, CROI GLP-1 in HIV.

7 stories · Covering clinical-trials, industry, research

Editor's Note

A quiet Saturday after the ENDO 2026 close, but worth catching up on five backdated stories that the post-ADA and post-ENDO cycles overshadowed. HLB Therapeutics' US subsidiary ReGenTree had missed the primary endpoint in the European SEER-3 Phase 3 trial of RGN-259, the thymosin beta-4 eye drop for neurotrophic keratitis — a stronger-than-expected placebo response in the control arm carried the trial; that result dates to June 2025, and the US SEER-2 Phase 3 was still underway. NervGen's first-quarter print confirmed its NVG-291 spinal cord injury peptide is on track for a mid-2026 RESTORE registrational Phase 3 in chronic tetraplegia after a successful End-of-Phase 2 FDA meeting, with blinded biomechanical gait-analysis results expected in Q2 2026 from the chronic cohort of the CONNECT SCI Phase 1b/2a. EndoCyclic Therapeutics quietly cleared an IND on March 23 for ENDO-205, a first-in-class non-hormonal precision peptide therapeutic for endometriosis, designed to eliminate lesions rather than suppress symptoms — a category where every prior drug has been a hormonal modulator. Bachem named CEO Anne-Kathrin Stoller to also assume the Chief Commercial Officer role May 25 after Torsten Wöhr's departure, consolidating leadership at one of the two CDMOs supplying the global GLP-1 API market. CROI 2026 in March featured a plenary talk by Johns Hopkins's Todd Brown framing GLP-1 receptor agonists as a potential cardiometabolic-and-beyond therapy for people living with HIV, with seven posters covering smoking reduction, liver fibrosis, gut tissue immune benefits, and cardiovascular risk. PharmTech's Friday roundup feature on peptide manufacturing best practices closes the week.

Correction (October 31, 2026): The RGN-259 item originally said HLB Therapeutics announced the SEER-3 miss in late May 2026. HLB announced it in June 2025, and the cited Ophthalmology Times report is dated July 1, 2025. We also removed two claims the source does not support: a second-half 2026 timeline for SEER-2 results and an ongoing ARISE-3 dry eye Phase 3.

Clinical Trials

HLB Therapeutics' ReGenTree Misses Primary Endpoint in European SEER-3 Phase 3 Trial of RGN-259 Thymosin Beta-4 Eye Drop for Neurotrophic Keratitis — Placebo Response Carries Control Arm

HLB Therapeutics (KOSDAQ: 115450) announced in June 2025, a year before this digest, that its US subsidiary ReGenTree failed to meet the primary endpoint in the European Phase 3 SEER-3 trial of RGN-259, a thymosin beta-4-based eye drop designed to rival Dompé's Oxervate (cenegermin) — the only FDA-approved prescription drop for neurotrophic keratitis. The trial did not show a statistically significant difference in complete corneal healing at 4 weeks compared to placebo, with a company spokesperson telling Korea Biomedical Review that 'a stronger-than-expected placebo effect in the control arm led to a puzzling outcome.' RGN-259 is licensed from RegeneRx. HLB Therapeutics CEO Ahn Gi-hong said the company would analyze the SEER-3 results and focus resources on the ongoing US Phase 3 SEER-2 trial.

#hlb-therapeutics #regn-259 #thymosin-beta-4 #neurotrophic-keratitis #ophthalmology #phase-3-fail #seer-3
Clinical Trials

NervGen NVG-291 RESTORE Registrational Phase 3 in Chronic Tetraplegia Targets Mid-2026 Initiation After FDA End-of-Phase 2 Alignment; Blinded Biomechanical Gait Analysis Expected Q2 2026 From CONNECT SCI Chronic Cohort

NervGen Pharma (Nasdaq: NGEN) confirmed in its Q1 2026 results (early May) that the RESTORE registrational Phase 3 study of NVG-291 in chronic tetraplegia (cervical chronic spinal cord injury, SCI) remains on track for mid-2026 initiation after a successful FDA End-of-Phase 2 meeting. NVG-291 is a subcutaneous peptide mimetic of the intracellular signaling domain of intracellular sigma peptide (ISP), designed to plasticize neural pathways and enable functional recovery in chronic SCI — a first-in-class mechanism where no pharmacological intervention has shown durable motor recovery before. The expanded chronic CONNECT SCI Phase 1b/2a data (n=10 active vs n=10 placebo) showed a three-fold increase in motor connectivity to the first dorsal interosseus hand muscle. Biomechanical gait analysis from an independent movement-intelligence firm is expected Q2 2026 to disentangle genuine neural recovery from compensatory mechanics. Cash was $16.6M as of March 31, 2026 (listed Nasdaq Jan 8, 2026).

#nervgen-pharma #nvg-291 #spinal-cord-injury #chronic-tetraplegia #intracellular-sigma-peptide #restore-phase-3 #non-glp-1
Clinical Trials

EndoCyclic Therapeutics ENDO-205 IND Cleared March 23, 2026: First-in-Class Non-Hormonal Precision Peptide Therapeutic for Endometriosis Designed to Eliminate Lesions Rather Than Suppress Symptoms

EndoCyclic Therapeutics announced FDA clearance of the Investigational New Drug (IND) application for ENDO-205 on March 23, 2026. ENDO-205 is a first-in-class non-hormonal precision peptide therapeutic for endometriosis, designed to eliminate lesions rather than modulate hormones — distinguishing it from all currently approved endometriosis therapies, which are either oral GnRH antagonists (elagolix, relugolix) or hormonal contraceptives. In preclinical models, ENDO-205 eliminated endometriosis lesions and associated inflammation with no safety signals in GLP toxicology studies. The Phase 1 will enroll healthy pre-menopausal women of reproductive age. Endometriosis affects roughly 10% of women of reproductive age globally, with a 6-10 year average diagnostic delay and no curative therapy.

#endocyclic-therapeutics #endo-205 #endometriosis #non-hormonal-peptide #precision-peptide #ind-clearance #women-health
Industry

Bachem CEO Anne-Kathrin Stoller Assumes Dual Role as CCO Effective May 25, 2026 After Torsten Wöhr's Departure — Leadership Consolidation at One of Two CDMOs Supplying Global GLP-1 API Market

Bachem AG (SIX: BANB) announced May 25, 2026 that Chief Commercial Officer Torsten Wöhr decided to pursue a new opportunity outside the company. CEO Anne-Kathrin Stoller — who succeeded Thomas Meier as CEO on January 1, 2026 after 19 years at Bachem in increasingly senior roles (Head of Business Development & Sales Europe, Chief Marketing Officer, COO Americas) — assumed the CCO role in addition to her CEO responsibilities until a successor is appointed. Bachem is one of two major peptide CDMOs supplying the global GLP-1 API market alongside PolyPeptide; the company is in the middle of multi-site capacity expansion across Switzerland (Bubendorf Module I completion H1 2026) and the US (San Diego, King of Prussia). The CCO transition follows months of senior turnover and comes as GLP-1 manufacturing capacity has become the rate-limiting constraint for the entire commercial peptide industry.

#bachem #peptide-cdmo #leadership-transition #glp-1-manufacturing #stoller #manufacturing
Industry

PharmTech Weekly Roundup (June 19, 2026): Peptide Manufacturing Best Practices Feature — Coordinated Lifecycle for Prefilled Syringe + Autoinjector Devices, Solvent-Free Fusion-Based Green Manufacturing

Pharmaceutical Technology's June 19, 2026 Weekly Roundup centered on two peptide-manufacturing best-practices features. Ajoy Koppolu argued that successful peptide manufacturing in prefilled syringes for high-speed autoinjectors requires a coordinated lifecycle approach integrating formulation design, Cpk-driven quality control, and factory acceptance testing to ensure consistent, compliant dose delivery — increasingly the bottleneck as injectable GLP-1, amylin, and triple-agonist peptides enter commercial scale. Separately, Elizabeth Hickman (CEO of AusteinPX) argued that early formulation and manufacturing decisions drive up to 80% of a drug's environmental impact, and that solvent-free, fusion-based alternatives to traditional spray-dried dispersion offer simultaneous operational and environmental gains — relevant as PolyPeptide and EMA both pursue greener GLP-1 manufacturing pathways.

#peptide-manufacturing #prefilled-syringe #autoinjector #green-manufacturing #pharmtech #drug-product
Research

CROI 2026 Plenary (Dr. Todd Brown, Johns Hopkins): GLP-1 Receptor Agonists Show Cardiometabolic, Smoking, Liver, and Gut Benefits in People Living With HIV — Seven Poster Presentations Plus an Oral Abstract

The Conference on Retroviruses and Opportunistic Infections (CROI 2026, March 9-12) featured an oral plenary by Dr. Todd Brown of Johns Hopkins Medicine titled 'GLP-1 Agonists: Are They a Cure for Everything?' alongside one oral abstract and seven posters on the use of GLP-1 receptor agonists in people living with HIV (PLWH). The findings: GLP-1s generally work well in PLWH, may improve liver fibrosis, gut tissue immune health, and cardiovascular risk, and may reduce smoking on top of the established weight loss and diabetes effects. One oral abstract suggested potential to reverse the gut damage that persists from very early HIV infection despite effective ART. Brown's plenary concluded the enthusiasm is warranted but flagged unanswered questions around long-term use and global access — particularly relevant for PLWH in low- and middle-income countries.

#croi-2026 #glp-1-hiv #todd-brown #johns-hopkins #plwh #cardiometabolic #real-world-evidence
Industry

Bloomberg / Wall Street Journal Recap: Lilly Mounjaro+Zepbound Reach 54.8% US GLP-1 Market Share vs Novo's 47% Year Earlier — 125%/80% YoY Growth in Mounjaro/Zepbound Q1 2026 Outpacing Novo's Wegovy Cycle

Coverage week of June 15-19 distilled the post-ADA market share story: Eli Lilly's tirzepatide franchise (Mounjaro for T2D, Zepbound for obesity) now holds 54.8% of US GLP-1 prescription share versus 47% a year earlier, with Q1 2026 YoY growth of 125% for Mounjaro and 80% for Zepbound and full-year revenue guidance raised to $82-85B. Novo Nordisk lifted its own 2026 guidance to a 4-12% currency-adjusted decline (improved from 5-13%) on Wegovy pill momentum (3M US scripts in five months, 65% of new prescriptions, 82% to GLP-1-naive patients), but Novo's stock has declined 42% over the past year against Lilly's 40% gain — the share-shift signal the ADA cycle crystallized. Lilly's seven additional retatrutide Phase 3 readouts across 2026 (TRIUMPH-7 chronic low-back pain, TRIUMPH-8 general obesity, TRIUMPH-9 obesity without T2D, plus OSA, MASLD, and cardiometabolic outcomes) extend the franchise gap.

#lilly #novo-nordisk #mounjaro #zepbound #wegovy-pill #market-share #retatrutide #ada-2026-wrap

Related Guides